Parameter | Overall cohort | Group 1 (3–4 × 106 CD34+ cells /kg bw) | Group 2 (2–2.5 × 106 CD34+ cells /kg bw) | P value Group 1 vs. 2 | Group 3 (< 2 × 106 CD34+ cells /kg bw) |
---|---|---|---|---|---|
ASCTs analyzed, n | 148 | 86 | 53 | Â | 9 |
G-CSF support, n (%) | Â | Â | Â | 0.271 | Â |
 Yes | 62 (42) | 34 (40) | 26 (49) | 2 (22) | |
 No | 86 (58) | 52 (60) | 27 (51) | 7 (78) | |
Leukocyte reconstitution | Â | Â | Â | 0.393 | Â |
 n available | 144 | 82 | 53 | 9 | |
 Days to L ≥ 1.0 × 109/L | 12 (9–24) | 12 (9–23) | 12 (10–24) | 12 (9–16) | |
Neutrophil reconstitution | Â | Â | Â | / | Â |
 n available | 42 | 17 | 23 | 2 | |
 Days to N ≥ 0.5 × 109/L | 14 (9–19) | 14 (9–19) | 13 (10–18) | 13 (11–14) | |
Aplasia | Â | Â | Â | 0.513 | Â |
 n available | 116 | 62 | 46 | 8 | |
 Days in aplasia | 9 (4–20) | 9 (4–19) | 8 (5–20) | 9 (5–13) | |
Platelet reconstitution |  |  |  | < 0.001 |  |
 n available | 144 | 85 | 51 | 8 | |
 Days to platelets ≥20 × 109/L | 12 (9–21) | 11 (9–16) | 13 (10–21) | 13 (9–19) | |
 n available | 81 | 55 | 23 | 0.001 | 3 |
 Days to platelets ≥50 × 109/L | 14 (10–22) | 14 (10–18) | 14 (13–22) | 15 (13–18) |